Clinical trials: Prostate Cancer, Castration Resistant
Prostate Cancer
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
- Trial name
- NCT00644488
- Testing
- BMS-641988 (AR#2)
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma
- Trial name
- NCT01338831
- Testing
- LFA102
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels…
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02215161
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Castrate Resistance Prostate Cancer
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel…
- Trial name
- NCT04113005
- Testing
- Desmopressin
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Advanced Solid Tumours
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
- Trial name
- NCT04564027
- Testing
- Ceralasertib
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
- Trial name
- NCT01810770
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 27 sites in China, Singapore and 2 more
- Volunteers
- 243 people
- Sponsor
- Bayer
Metastatic Castration-Resistant Prostate Cancer Patients
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic…
- Trial name
- NCT03643107
- Testing
- Irofulven, Prednisolone 10 mg
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Allarity Therapeutics
Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
This phase Ib trial is to find out the best dose decitabine/cedazuridine and possible benefits and/or side effects of decitabine/cedazuridine and enzalutamide in treating patients with castrate resistant prostate cancer that has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05037500
- Testing
- Decitabine and Cedazuridine, Enzalutamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic…
- Trial name
- NCT06457919
- Testing
- Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration Resistant Prostate Cancer
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
- Trial name
- NCT01540071
- Testing
- NRX 194204
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Io Therapeutics
Cancer, Metastatic Castration-resistant Prostate Cancer
Study of INKmune in Patients With mCRPC (CaRe Prostate)
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart.
- Conditions
- Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
- Trial name
- CaRe (NCT06056791)
- Testing
- INKmune
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inmune Bio, Inc.
Prostate Cancer
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Primary Objective: To demonstrate the non inferiority in term of overall survival (OS) of Cabazitaxel 20 mg/m² (Arm A) versus Cabazitaxel 25 mg/m² (Arm B) in combination with prednisone in participants with metastatic castration…
- Trial name
- PROSELICA (NCT01308580)
- Testing
- Cabazitaxel (XRP6258), Prednisone (or Prednisolone)
- Where
- 172 sites in United States, Argentina and 20 more
- Volunteers
- 1,200 people
- Sponsor
- Sanofi
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT02012920
- Testing
- Seviteronel: given orally once daily in 28 day cycles
- Where
- 23 sites in United States, Greece and 2 more
- Volunteers
- 200 people
- Sponsor
- Innocrin Pharmaceutical
Prostate Cancer Metastatic
A Phase 1/2 Trial of ADI-212 in mCRPC
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- NCT07793435
- Testing
- ADI-212, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Adicet Therapeutics
Prostate Cancer, Prostate Neoplasms
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
This study is to evaluate safety, tolerability pharmacokinetics and efficacy of MDV3100 after oral administration to patients with castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Neoplasms, Castration Resistant Prostate Cancer (CRPC)
- Trial name
- NCT01284920
- Testing
- MDV3100
- Where
- 7 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Astellas Pharma Inc
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
This study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07311694
- Testing
- HRS-4357 injection, Enzalutamide；Abiraterone
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior…
- Trial name
- NCT01414296
- Testing
- PSMA ADC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer Metastatic
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
This phase IIb study is a randomized, double-blind, placebo-controlled multi-center study evaluating efficacy and tolerability of Osteodex of patients with metastatic castration resistant prostate cancer (CRPC).
- Trial name
- NCT02378870
- Testing
- Osteodex
- Where
- Sweden
- Volunteers
- 3 people
- Sponsor
- DexTech Medical AB
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC)…
- Trial name
- NCT04060394
- Testing
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Where
- 17 sites in United States, South Korea
- Volunteers
- 49 people
- Sponsor
- Laekna Limited
Metastatic Castration-resistant Prostate Cancer, mCRPC
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection
This proposal is a phase I, open-label study of a 3-Dose Regimen of Escalating Doses of 177Lu-LNC1003 Injection in patients with PSMA-positive mCRPC. In the clinical development, we aim to demonstrate the following: 1.
- Trial name
- NCT06237491
- Testing
- 177Lu-LNC1003 Injection group 1, 177Lu-LNC1003 Injection group 2, 177Lu-LNC1003 Injection group 3
- Volunteers
- 12 people
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.